NCT03070990 - A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

February 25, 2019

Study Completion Date

February 25, 2019

Conditions

Metastatic Urothelial Cancer

Interventions

DRUG

Enfortumab vedotin

All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.

Trial Locations (8)

Unknown

Site JP00003, Tsukuba

Site JP00005, Sendai

Site JP00008, Suita

Site JP00004, Chuo-ku

Site JP00007, Koto-ku

Site JP00006, Fukuoka

Site JP00001, Niigata

Site JP00002, Okayama